Safety of filgotinib in patients with rheumatoid arthritis: Analysis of lymphocytes in the long-term extension FINCH 4 study

^{Jacques Eric Gottenberg, Gerd Burmester, Katrien Van Beneden, Chris Watson, Ineke Seghers, Vijay Rajendran, Lorenzo Dagna, Maya H Buch and Gerhard Rogler}

Effect of filgotinib (FIL) on body weight (BW) and body mass index (BMI) and effect of baseline BMI on the efficacy and safety of FIL in rheumatoid arthritis (RA)

^{Alejandro Balsa, Siegfried Wassenberg, Anne Tournadre, Hans-Dieter Orzechowski, Katrien Van Beneden, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, Patrick Verschueren}

Efficacy and safety of filgotinib in patients aged ≥75 years: a post hoc subgroup analysis of the FINCH 4 long-term extension (LTE) study

^{Daniel Aletaha, René Westhovens, Bernard G Combe, Jacques-Eric Gottenberg, Maya H Buch, Roberto Caporali, Jose A Gómez-Puerta, Paul van Hoek, Vijay Rajendran, Pieter-Jan Stiers, Thijs Hendrikx, Gerd R Burmester, Yoshiya Tanaka}

The use of exposure-adjusted event rates versus exposure-adjusted incidence rates in adverse event reporting: insights from filgotinib integrated safety data in rheumatoid arthritis

^{Patrick Durez, Eugen Feist, Ricardo Blanco, Vijay Rajendran, Nadia Verbruggen, Katrien Van Beneden, James Galloway}

Clinical outcomes up to Week 48 of ongoing filgotinib (FIL) rheumatoid arthritis (RA) long-term extension (LTE) trial of biologic disease-modifying antirheumatic drug (bDMARD) inadequate responders (IR) initially on FIL or placebo in a Phase 3 parent study (PS)

^{Maya H. Buch, Tsutomu Takeuchi, Vijay Rajendran, JE Gottenberg, Alena Pechonkina, YingMeei Tan, Qi Gong, Katrien Van Beneden, Roberto Caporali}

Integrated safety analysis update for filgotinib (FIL) in patients (pts) with moderately to severely active rheumatoid arthritis (RA) receiving treatment over a median of 2.2 years (y)

^{Kevin Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan J Kivitz, Mark C Genovese, Alena Pechonkina, Franziska Matzkies, Beatrix Bartok, Kun Chen, Deyuan Jiang, Iyabode Tiamiyu, Robin Besuyen, Sander Strengholt, Gerd R Burmester, Jacques-Eric Gottenberg}

Clinical outcomes of methotrexate (MTX)-naïve rheumatoid arthritis (RA) patients (pts) on filgotinib (FIL) long-term extension (LTE) trial initially on FIL or MTX during the Phase 3 parent study (PS)

^{Daniel Aletaha, Rene Westhovens, Tatsuya Atsumi, YingMeei Tan, Alena Pechonkina, Qi Gong, Vijay Rajendran, Sander Strengholt, Gerd Rudiger Burmester}

Clinical outcomes up to Week (W) 48 in the ongoing filgotinib (FIL) long-term extension (LTE) trial of rheumatoid arthritis (RA) patients (pts) with inadequate response (IR) to methotrexate (MTX) initially treated with FIL or adalimumab (ADA) during the Phase 3 parent study (PS)

^{Bernard Combe, Yoshiya Tanaka, Paul Emery, Alena Pechonkina, Albert Kuo, Qi Gong, Katrien Van Beneden, Vijay Rajendran, Hendrik Schulze-Koops}

Efficacy and safety of filgotinib in patients with inadequate response to methotrexate, with or without 4 poor prognostic factors: A post hoc analysis of the FINCH 1 study

^{Bernard Combe, Yoshiya Tanaka, Maya H. Buch, Gerd Burmester, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Thijs Hendrikx, Daniel Aletaha}

Radiographic change in patients with rheumatoid arthritis and estimated baseline yearly progression ≥5 or <5: post hoc analysis of two phase 3 trials of filgotinib

^{Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Robert B M Landewé, Beatrix Bartok, Alena Pechonkina, Zhaoyu Yin, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi}